Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion type Assertion NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_head.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion description "[Moreover, agents targeting bone biology (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_provenance.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion evidence source_evidence_literature NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_provenance.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion SIO_000772 22215754 NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_provenance.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion wasDerivedFrom befree-2016 NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_provenance.
- NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_assertion wasGeneratedBy ECO_0000203 NP950747.RA2rRJLWnfj3xiS9myg_SoDRw4yfNEO71Xmk4ts2quBK8130_provenance.